Agios Pharmaceuticals Receives FDA Extension for Pyrukynd Review

Author: Thomas Cooper Updated: 09-04-2025 10:57 AM

FDA Grants Additional Time for Pyrukynd Review

On a recent Thursday, Agios Pharmaceuticals, Inc. faced a notable delay as the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for their supplemental New Drug Application (sNDA) concerning Pyrukynd (mitapivat). This is the first application primarily focused on adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha or beta-thalassemia, now pushed to a new review target of December 7, 2025.

Importance of the REMS Submission

This extension is attributed to a recent request from the FDA for more comprehensive information, prompting Agios to submit a proposed Risk Evaluation and Mitigation Strategy (REMS). The REMS aims to address concerns regarding potential hepatocellular injury that has been previously noted in discussions surrounding Pyrukynd’s sNDA.

Impact on Review Timeline

The addition of the REMS is considered a significant alteration to the original Pyrukynd sNDA, resulting in the aforementioned three-month review extension. Importantly, this delay does not stem from new or further efficacy or safety data being requested from Agios by the FDA.

Phase 3 Trials Supporting the Application

The submission of the sNDA is backed by positive outcomes from two pivotal Phase 3 trials, known as ENERGIZE and ENERGIZE-T, which examined adults with NTD and TD forms of alpha or beta-thalassemia, respectively.

International Approvals and Collaborations

Additionally, in a promising development last month, the Saudi Food and Drug Authority (SFDA) granted approval for Pyrukynd for use among adult patients with both forms of thalassemia. Looking ahead, Agios has entered into a distribution agreement with NewBridge Pharmaceuticals to facilitate regulatory filings and market Pyrukynd across the Gulf Cooperation Council (GCC) region, encompassing countries like Saudi Arabia and the UAE.

Pyrukynd's Existing Approvals

Pyrukynd is not only sought for thalassemia treatment but also has gained approval for treating hemolytic anemia in adults suffering from pyruvate kinase (PK) deficiency in the U.S. market, along with its recognition for PK deficiency in the European Union and Great Britain.

Current Market Response

The market has shown a downturn in response to these developments, with AGIO stock witnessing a decrease of 15.83%, currently trading at $34.18. This adjustment reflects investor responses to the news surrounding the extended review timeline and potential implications for future earnings.

Frequently Asked Questions

What is Pyrukynd used for?

Pyrukynd is used for treating conditions like alpha and beta-thalassemia, as well as hemolytic anemia related to PK deficiency.

What does the FDA review extension mean for Agios Pharmaceuticals?

The extension means Agios needs to wait an additional three months for the FDA's final decision on Pyrukynd's application, potentially affecting their market strategy.

How does the REMS impact the drug's approval?

The REMS is designed to ensure that patients are adequately informed of risks associated with the treatment, which can affect the overall approval process and timeline.

What trials support Pyrukynd's application?

The application is supported by results from the ENERGIZE and ENERGIZE-T Phase 3 trials, which tested the drug's effectiveness in adults with both forms of thalassemia.

What recent approvals has Pyrukynd received?

Recently, Pyrukynd was approved by the Saudi Food and Drug Authority for adult patients with thalassemia, expanding its market presence internationally.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.